onlyuseINVESTOR PRESENTATION

nalNOVEMBER 2021

2

ANNUAL REPORT TEMPLATE

MINIMAL DESIGN 2016/2107

nal use only

Positioning for Growth

(ASX: RHT)

INVESTOR PRESENTATION

NOVEMBER 2021

3

DISCLAIMER

nal use only

This presentation has been prepared by Resonance Health Ltd ("Resonance Health" or "Company") and may contain forward-looking statements that are based on current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described. Forward looking statements contained in this presentation may include statements about future financial and operating results, status of regulatory submissions, possible or assumed future growth opportunities and risks and uncertainties that could affect Resonance Health's products and services.

These forward looking statements are not guarantees of future performance, involve certain risks, uncertainties and assumptions that are difficult to predict, and are based upon assumptions as to future events that may prove inaccurate. Actual outcomes and results may differ materially from what is expressed in any forward looking statement in which Resonance Health expresses an expectation or belief as to future results. There can be no assurance that the statement or expectation or belief will result or be achieved or accomplished. Resonance Health will not update forward-looking statements unless required by law.

This presentation does not constitute or form part of an offer of securities or a solicitation of invitation to buy or apply for securities, nor may it or any part of it form the basis of, or be relied on in any connection with any contract or commitment. The information in this presentation does not take into account the objectives, financial situation or particular needs of any person. Nothing contained in this presentation constitutes investment, legal, tax, or other advice. Potential investors should make their own decisions whether to invest in Resonance Health shares based on their own enquiries and are advised to seek appropriate independent advice. This presentation does not, and does not purport to, contain all the information prospective investors in Resonance Health would desire or require in reaching an investment decision.

To the maximum extent possible by law, none of Resonance Health, their officers, directors, employees, associates, or agents, nor any other person's accepts any liability for any loss, claim, damages, costs or expenses of whatever nature (whether or not foreseeable), including, without limitation, any liability arising from fault or negligence on the part of any of them or any other person, for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it or any error or omissions in it.

4

NOVEMBERANNUAL EPORT2021

TEMPLATE

INVESTORMINIMALPRESENTATIONDESIGN 2016/2107

onlyASX: RHT

• Australian medical technology company

• Early adopter of AI in medical imaging

• Gold standard in LIC with FerriScan

• Products and services sold in over 500 centres use• Strong IP position, several patents

• Supplemented by global channel partners

• Six regulatory cleared medical devices

• Two regulatory cleared AI medical devices

• Recent transitional period completed nal

Resonance Health is a global leader in the diagnosis and measurement of iron or fat in human organs, including the liver, heart, spleen, and brain.

Mission

To develop innovative healthcare products and services, to work diligently to deliver the highest quality products for customers and patients, and to operate with integrity and excellence in driving growth for shareholders.

Values

  • Innovation
  • Integrity
  • Leadership
  • Service
  • Quality

Core Business

Resonance Health is an Australian medical-technology company with several regulatory cleared and deployed medical products related to iron and fat in human organs and a high-impact pipeline of new, near, medium, and long term research and development products.

INVESTOR PRESENTATION

NOVEMBER 2021

PRESENTATION OUTLINE

5

nal use only

  1. New Global Salesforce
  2. Introducing LiverSmart™
  3. Prolific (and growing) Diseases
  4. High Impact Innovation and R&D

Share Price

ASX

Share price Shares on issue Market Capitalisation Cash at Bank Enterprise Value Top 20 Shareholders Board & Management

RHT(* at 24/11/21)

0.12*

461.1m

$55.33m*

$8.4m (30/9)

$63.73m*

50.2%

20.3%

Last 5 Years

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Resonance Health Limited published this content on 25 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 November 2021 01:19:01 UTC.